Prothena Corporation PLC banner

Intrinsic Value

The intrinsic value of Prothena Corporation PLC (0PT) under the Base Case is 6.077 EUR per share. Compared with the current market price of 7.208 EUR, the stock appears Overvalued by 16% .

The intrinsic value is the average of valuations using the DCF method and multiples.

Do our valuations actually work? See backtest results .

0PT Intrinsic Value
€6.077
Overvaluation 16%
Intrinsic Value
Price €7.208

0PT is cheaper than usual. Still overvalued, but less so than on more than 99% of days in the past 5 years.

Alert me when 0PT is below its intrinsic value
Today €4.861 · 32.6% below the current price
Alternatives to 0PT

Fundamental Analysis

What Prothena Does

Biotechnology Health Care

Prothena Corporation PLC is a biotechnology company that focuses on diseases caused by harmful proteins, especially neurodegenerative disorders and certain rare amyloid-related conditions. It does not sell a broad line of commercial medicines; instead, it develops drug candidates intended to stop or slow the protein misfolding and buildup that drives these illnesses.

Headquarters
Ireland IE
Employees
67
IPO date
Dec 21, 2012
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Prothena insiders are selling less than usual

Insider trading · Last trade on Oct 23, 2026

Sold $136k 2 insiders
Bought $10.6m 1 insider
Trades by date
Open insider trading

Past 12 months

Continue 0PT Research

Decided on Prothena? Get an email when 0PT reaches the price you’d buy at. Free with an account.

Other Prothena listings

What is the Intrinsic Value of one 0PT stock?

The intrinsic value for Prothena Corporation PLC (0PT) under the Base Case is 6.077 EUR.

Is 0PT stock undervalued or overvalued?

Compared with the current market price of 7.208 EUR, the stock appears Overvalued by 16% .

How reliable are our estimates? See how past valuations played out
Back to Top